The authors note that Chinese companies are eager to bring foreign innovative technologies to China, and, despite trade tensions between the U.S. and China, cross-border technology transfers into China, especially in the life sciences area, have remained active. Janet and Can then breakdown how these technology transfers are being regulated through China’s technology import and export regulations (TIER), including how a recent amendment to TIER has impacted the space.
Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized by More ›
Dr. Can Cui is a member of the firm’s Technology Transactions Group and one of the leading practitioners in biotech and life sciences recognized by Berkeley Center for Law & Technology. His practice focuses on China-related life sciences transactions, including cross-border technology licensing and acquisitions, collaboration and strategic partnerships, joint ventures, and other forms of investments. Can has extensive experience representing both technology licensors and More ›